

TABLE OF CONTENTS

0. Executive Summary	19
1. Clinical Features, Epidemiology and Pathology	21
Introduction.....	21
Historical aspects.....	21
Clinical features of Alzheimer disease.....	22
Seven stages of Alzheimer disease	24
AD as a terminal illness	26
Detection of AD in the preclinical phase	26
Differentiation of AD from other dementias	26
Differentiation of AD from non-dementing disorders	27
Cerebral insufficiency and AD	28
Memory deficits and preclinical AD	28
Mild cognitive impairment	29
Evolution of diagnostic criteria of AD	31
Revised criteria for the clinical diagnosis of AD	32
Epidemiology	33
Epidemiology of aging	33
Epidemiology of dementia	35
Epidemiology of AD	35
<i>Prevalence of AD according to age</i>	<i>36</i>
<i>Mortality in AD.....</i>	<i>36</i>
Pathophysiology of AD	37
Cerebral atrophy and neuronal loss	37
Neuritic plaques and neurofibrillary tangles	37
Sp proteins as markers of neuronal death in AD.....	38
Role of tau in the pathogenesis of AD	38
Amyloid precursor protein	39
<i>Relation of APP mutations to CNS disorders.....</i>	<i>40</i>
<i>Relation of APP to Aβ deposits and pathogenesis of AD</i>	<i>40</i>
<i>APP intracellular domain</i>	<i>42</i>
<i>Role of secretases in amyloid cascade.....</i>	<i>42</i>
<i>Role of exosomal proteins</i>	<i>44</i>
<i>Role of nicastrin</i>	<i>44</i>
Neurotoxicity of A β deposits	44
<i>Relation of Aβ deposits to synaptic activity</i>	<i>45</i>
<i>Dysfunction of TGF-β signaling accelerates Aβ deposition</i>	<i>45</i>
<i>Role of TMP21 in presenilin complexes and Aβ formation.....</i>	<i>45</i>
<i>Role of Aβ dimers in the pathogenesis of AD.....</i>	<i>46</i>
<i>Structure-neurotoxicity relationships of Aβ oligomers.....</i>	<i>46</i>
A β deposit and clearance	46
Impairment of mitochondrial energy metabolism	47
<i>Aβ-binding alcohol dehydrogenase links AD to mitochondrial toxicity</i>	<i>48</i>
Neural thread protein	48
Loss of synaptic proteins.....	48
<i>AD and Down syndrome.....</i>	<i>49</i>
<i>Overlapping pathologies of AD and Parkinson disease</i>	<i>49</i>
<i>AD and age-related macular degeneration.....</i>	<i>50</i>
<i>Myelin hypothesis of AD.....</i>	<i>50</i>
<i>Blood-brain barrier in AD</i>	<i>50</i>
<i>Blood vessel damage in AD</i>	<i>52</i>
<i>Loss of serotonin 1A receptors in the brain.....</i>	<i>52</i>
Factors in pathogenesis of AD.....	52
<i>Aerobic glycolysis and AD.....</i>	<i>52</i>
<i>Astrocytes and AD.....</i>	<i>52</i>
<i>Axonal transport failure in AD.....</i>	<i>53</i>
<i>Cell-cycle hypothesis</i>	<i>53</i>
<i>Chronic heart failure link with AD</i>	<i>54</i>
<i>Creatine and AD.....</i>	<i>54</i>
<i>Disturbances of interaction of nervous system proteins.....</i>	<i>54</i>
<i>DENN/MADD expression and enhanced pro-apoptotic signaling in AD.....</i>	<i>54</i>
<i>Gonadotrophins and AD</i>	<i>55</i>
<i>Glutamate transport dysfunction in AD</i>	<i>55</i>
<i>Innate immune system and AD.....</i>	<i>56</i>
<i>Insulin, diabetes and AD</i>	<i>57</i>
<i>Mechanisms underlying cognitive deficits in AD.....</i>	<i>57</i>
<i>Monoamine oxidase and AD.....</i>	<i>58</i>
<i>Neuroinflammation and AD.....</i>	<i>58</i>

Neurotransmitter deficits.....	59
Neurotrophic factors.....	60
NF- κ B signaling and the pathogenesis of neurodegeneration.....	60
Nitric oxide and AD.....	61
Nogo receptor pathway.....	63
Oxidative stress and AD.....	63
Prostaglandins and AD.....	65
Quinolinic acid and AD.....	65
Retromer deficiency.....	65
Serotonin and AD.....	66
Spherotoxin.....	66
Synaptic failure in AD.....	66
Transmission of AD.....	67
Ubiquitin-proteasome system in pathogenesis of AD.....	67
Risk factors in the etiology of AD.....	68
Aging and developmental abnormalities of the cholinergic system.....	69
Cholesterol, dietary lipids, and A β	69
Exposure to magnetic fields.....	70
Family history of AD.....	70
Homocysteine and AD.....	70
Level of education/type of job and risk of AD.....	71
Metals and AD.....	72
Obesity.....	73
Proneness to psychological distress and risk of AD.....	74
Reduced muscle strength.....	74
Sleep deprivation.....	74
Traumatic brain injury and AD.....	75
Vascular risk factors for AD.....	76
Vitamin B12 and folate.....	77
AD versus non-dementing changes in the aging brain.....	77
AD and cognitive impairment with aging.....	78
Pathomechanism of memory impairment and AD.....	78
Concluding remarks on pathophysiology of AD.....	79
Genetics of AD.....	80
Familial AD.....	80
<i>Presenilins and calcium channel leak in pathogenesis of familial AD</i>	82
Late onset AD.....	82
Genomics of AD.....	82
Introduction to genomics.....	82
Genes associated with Alzheimer disease.....	83
<i>AlzGene database</i>	84
<i>ApoE gene</i>	84
<i>ApoE genotype and nitric oxide</i>	85
<i>ApoE genotype modulates AD phenotype</i>	86
<i>APOE genotype and age-related myelin breakdown</i>	86
<i>ApoE receptor interaction with NMDA receptor</i>	87
<i>ApoE and ApoER2</i>	87
<i>ApoE receptor LR11 as regulator of Aβ</i>	88
<i>Arctic mutation</i>	88
<i>CALHM1 polymorphism and AD</i>	88
<i>CLU, CRI and PICALM</i>	88
<i>CYP46 and risk for AD</i>	89
<i>DAPK1 gene variants and AD</i>	89
Genetic variants associated with late-onset AD.....	89
<i>Copy number variation (CNV) in LOAD</i>	90
<i>LRRTM3 as a candidate gene for AD</i>	90
<i>MTHFD1L gene variant associated with AD</i>	90
<i>OGG1 mutations associated with AD</i>	91
<i>SORL1 gene in AD</i>	91
<i>TOMM40 gene and risk of AD</i>	91
International Genomics of Alzheimer's Project.....	91
Molecular neuropathology.....	92
Role of microRNAs in AD.....	92
AD as a polygenic disorder.....	93
Proteomics of AD.....	93
Introduction.....	93
Application of proteomic technologies to study AD.....	93
Protein misfolding in AD.....	95
Common denominators of AD and prion diseases.....	96
<i>Amyloid fibrils as a common feature of AD and prion diseases</i>	97
FE65 proteins and AD.....	97

2. Diagnostic Procedures for Alzheimer Disease	99
Importance of the diagnosis of Alzheimer disease	99
Methods of diagnosis of AD	99
Self-administered olfactory test	100
Neuropsychological testing	100
Assessment and evaluation	101
7-minute screen	101
15-point risk index	102
Measurement of aggregation in anterior segment of the eye	102
Activities of Daily Living	102
Alzheimer Disease Cooperative Study	103
CDR-SOB score	103
Clinician's Interview-Based Impression of Change	103
Resource Utilization in Dementia Battery	103
DETECT™ System	103
Electrophysiology	104
EEG-based bispectral index	104
Event-related potentials	104
Correlation of electrical activity of the brain with cognition	104
Early detection of cataract associated with AD	105
Retinal imaging to detect A β deposits	105
Laboratory methods for diagnosis of AD	105
Monitoring of synthesis and clearance rates of A β in the CSF	105
Molecular diagnostics for AD	106
Genetic tests for AD	107
ApoE genotyping	107
Gene expression patterns in AD	108
Molecular fingerprinting of the immune system in AD	108
Microarray-based tests for AD	108
Monoclonal antibody-based in vitro diagnosis of AD from brain tissues	109
Biomarkers of AD	109
The ideal biomarker for AD	111
CSF biomarkers of AD	111
CSF sulfatide as a biomarker for AD	111
Glycerophosphocholine as CSF biomarker in AD	112
Protein biomarkers of AD in CSF	112
Amyloid precursor protein	114
Tau proteins in CSF	114
Tests for the detection of A β in CSF	114
Tests combining CSF tau and A β	115
Urine tests for AD	115
Blood tests for AD	116
Blood A β levels	116
Blood test for AD based on heme oxygenase-1	117
Blood test for AD based on RNA hybridization	117
GSK-3 elevation in white blood cells	117
Lymphocyte Proliferation Test	118
Protein kinase C in red blood cells	118
Sphingolipids	118
Tests based on protein biomarkers in blood	118
A skin test for early detection of AD	119
Saliva-based tests for AD	119
Saliva A β 42 level as a biomarker of AD	119
Nanotechnology to measure A β -derived diffusible ligands	120
Simultaneous measurement of several biomarkers for AD	120
Plasma biomarkers of drug response in AD	121
A serum protein-based algorithm for the detection of AD	121
Concluding remarks about biomarkers for AD	121
Imaging in AD	122
Computed tomography	122
Magnetic resonance imaging	122
Arterial spin labeling with MRI	123
Magnetic resonance microscopy	123
Magnetic resonance spectroscopy	123
Single photon emission computed tomography and modifications	124
Positron emission tomography	125
In vivo imaging of A β deposits by PET	126
Pittsburgh compound B and PET	127
Florbetapir-PET	128
Florbetaben-PET	128
In vivo detection of A β plaques by MRI	129

Imaging agents for A β and neurofibrillary tangles	129
Targeting of a chemokine receptor as biomarker for brain imaging	130
Radioiodinated cloquinol as a biomarker for A β	130
Imaging neuroinflammation in AD	130
Preclinical diagnosis of AD	131
Meta-analysis of literature on imaging in AD	132
Alzheimer Disease Neuroimaging Initiative	132
Concluding remarks on imaging for diagnosis of AD	133
Diagnosis of MCI and prediction of AD	133
Diagnosis of MCI	133
<i>Computer-Administered Neuropsychological screen for MCI</i>	133
<i>Infrared eye-tracking technology to detect MCI</i>	133
<i>PET for detection of MCI</i>	134
<i>MRI for detection of MCI</i>	134
Presymptomatic detection of AD	134
PredictAD project	135
Prediction of AD in patients with MCI	135
<i>Combination of MMSE and a memory test for prediction of AD</i>	135
<i>Biochemical biomarkers in CSF for prediction of AD</i>	135
<i>Structural MRI biomarkers for prediction of AD</i>	136
<i>Magnetoencephalography for detection of MCI and AD</i>	136
<i>Concluding remarks about prediction of AD in MCI</i>	137
Criteria for diagnosis of AD	137
Role of biomarkers in diagnosis of AD dementia	138
Ethical aspects of diagnostics for AD	138
Genetic testing for AD	138
Ethical issues of brain imaging in AD	139
Companies involved in diagnosis of AD	139
3. Management of Alzheimer Disease	141
Introduction	141
Cholinergic approaches	141
Mechanism of action of cholinesterase inhibitors	142
Choline and lecithin	143
Donepezil	144
Rivastigmine	145
Galantamine	146
Duration of treatment with ChE inhibitors	147
Comparative studies of ChE inhibitors	147
Donepezil versus rivastigmine	148
Donepezil versus galantamine	148
An assessment and future prospects of anticholinergic therapies	148
Neuroprotection in Alzheimer's disease	149
Memantine	150
<i>Combination of memantine with ChE inhibitors</i>	153
Monoamine oxidase inhibitors	153
<i>Selegiline</i>	154
Synaptoprotection in AD	154
Drugs for noncognitive symptoms in AD	154
Antidepressants	154
Antipsychotics	155
ChE inhibitors for behavioral and psychological disorders in AD	155
Concluding remarks and other drugs for agitation in AD	156
Sensory stimulation	156
Non-pharmacological treatments of AD	157
Management of memory loss in AD	157
Exposure to electromagnetic fields for treatment of AD	158
<i>Application of electrical fields for improvement of cerebral function</i>	158
<i>High-frequency electromagnetic field treatment of AD</i>	158
Vagal nerve stimulation	158
Cerebrospinal fluid shunting	159
Omental transposition	160
Microchip-based hippocampal prosthesis for AD	160
Nutritional therapies for AD	160
<i>Axona</i>	160
<i>Cocktail of dietary supplements for AD</i>	160
<i>Docosahexaenoic acid</i>	161
<i>Magnesium</i>	162
<i>Nicotinamide for the treatment of AD</i>	163
<i>Omega-3 fatty acids</i>	163
Preventing decline of mental function with aging and dementia	164

Prevention of Alzheimer disease	164
<i>Mental training</i>	165
<i>Physical exercise</i>	165
<i>Higher level of conscientiousness and decreased risk of AD</i>	166
<i>Caloric restriction</i>	166
<i>Nutritional factors in prevention of AD</i>	167
<i>Grapes and red wine</i>	167
<i>Black and green teas</i>	168
<i>Caffeine</i>	169
Drugs to prevent Alzheimer disease	169
Preimplantation genetic diagnosis of inherited Alzheimer disease	169
Presymptomatic detection of AD	170
Management of mild cognitive impairment	170
Management of Down syndrome	171
Guidelines for use of anti-dementia drugs in clinical practice	172
Donepezil and/or memantine	173
General care of the Alzheimer disease patients	173
Strategies for the management of Alzheimer disease	173
4. Research in Alzheimer Disease	175
Introduction	175
Animal models of Alzheimer disease	175
Lesional models	175
<i>Cerebroventricular injection of Aβ in rats</i>	175
<i>Lentiviral vector-based models of amyloid pathology</i>	176
<i>AAV-mediated gene transfer to increase hippocampal Aβ</i>	176
Transgenic mouse models	176
<i>Quantitative assessment of amyloid load in transgenic models</i>	178
<i>In vivo magnetic resonance microimaging in transgenic models of AD</i>	178
<i>Transgenic model of AD with suppression of Aβ production</i>	178
<i>Transgenic AD11 anti-NGF mice</i>	179
<i>Genetically altered mice with deficiency of vesicular ACh transporter</i>	179
<i>Limitations of mouse models of Alzheimer disease</i>	179
Cholesterol-fed rabbits as models for AD	180
Zebrafish model for AD	180
Transgenic invertebrate models of Alzheimer disease	181
<i>Drosophila model of AD</i>	181
<i>Caenorhabditis elegans Alzheimer disease model</i>	182
Cell systems for AD research	182
In vitro neuronal cell Lines	182
Single-gene expression system for use in cell culture	183
Transgenic cells	183
In silico models	184
Estimation of progression rates of Alzheimer disease	184
Clinical trial methods in Alzheimer disease	185
Molecular imaging as a guide to drug development	185
<i>Use of MRI and PET in clinical trials</i>	186
Cognitive-function assessment in clinical trials	186
Clinical trials in mild cognitive impairment	187
Research in AD as a basis for future therapies	187
Use of microarrays for studying pathogenesis of AD	187
Computational brain mapping in AD	187
Study of neurogenesis in AD	188
Study of 3D structure of A β	188
Solid-state NMR to study precursors of A β	188
Research in Alzheimer disease at academic centers	188
Role of NIH in AD research	189
NIH Clinical Trials Database for AD	189
Alzheimer Research Consortium	189
The National Institute on Aging and AD research	189
5. Drug Discovery & Development for Alzheimer Disease	191
Introduction	191
Categories of drugs in development for AD	191
Memory-enhancing drugs	193
Enhancing memory by drugs that block eIF2 α phosphorylation	193
Drugs based on cholinergic approaches	193
AP2238	194
Butyrylcholinesterase inhibitors	194
Donepezil-tacrine hybrids	194
Drugs modulating gamma-aminobutyric acid receptors	195

Ganstigmina	195
Methanesulfonyl fluoride	195
Muscarinic receptor modulators	196
<i>Muscarinic M1 agonists</i>	196
<i>Muscarinic M2 antagonists</i>	197
Nicotine and nicotinic receptor modulators	197
<i>Nicotine</i>	197
<i>Nicotinic receptor modulators</i>	198
<i>GTS21</i>	199
<i>Ispronicline</i>	199
<i>JWB1-84-1</i>	200
Neuropeptide/neurotransmitters	200
Somatostatin release enhancers	200
Glutamate receptor modulators	200
Physiology and pharmacology of glutamate receptors	201
NMDA receptor ion channel complex	201
Metabotropic glutamate receptors	203
Glutamate receptor modulators as potential therapeutics for AD	204
<i>Non-competitive NMDA modulators</i>	205
<i>AMPA modulators</i>	205
Drugs affecting multiple neurotransmitters	206
Ensaculin	206
NS2330	206
RS-1259	206
Lecozotan	207
Vaccines for AD	207
Active immunization with A β	208
<i>AN-1792 vaccine</i>	208
<i>Complications in clinical trials with AN-1792</i>	208
<i>Effects of Aβ vaccine on the brain</i>	208
Strategies to avoid undesirable effect of A β vaccination	209
Passive immunization in AD	210
<i>Passive immunization with MAbs</i>	210
<i>Delivery of the passive antibody directly to the brain</i>	212
<i>Systemic injection of MAbs to treat AD</i>	213
Combination of A β immunotherapy and CD40-CD40L blockade	213
Shaping the immune responses elicited against A β	213
Delivery of AD vaccines	214
<i>Gene vaccination</i>	214
<i>Modified Aβ nasal vaccine</i>	214
<i>Transdermal Aβ vaccination</i>	214
Other vaccines for AD	215
<i>Nasal vaccination with Proteosome™ adjuvant</i>	215
<i>T-cell vaccination with glatiramer acetate adjuvant</i>	216
Early start of immunotherapy to clear A β plaques	216
Reversal of cholinergic dysfunction by anti-A β antibody	216
Immune modulation via TRL9 to reduce A β	216
Mechanisms by which A β antibodies reduce amyloid accumulation in the brain	217
Perspectives on vaccines for AD	217
Companies involved in AD vaccines	219
Inhibition of amyloid precursor protein aggregation	220
Secretase modulators	220
<i>Neuroprotection by α-secretase cleaved APP</i>	221
<i>Inhibitors of β-secretase</i>	221
<i>Inhibitors of γ-secretase</i>	222
Amyloid-derived diffusible ligands	223
GABA receptor modulation by etazolate and APP processing	224
Depletion of serum amyloid P	224
Trojan-horse approach to prevent build-up of A β aggregates	224
Drugs that inhibit the formation of Aβ	225
22R-hydroxycholesterol	225
Acylaminopyrazole	226
Cadmium telluride nanoparticles prevent A β fibril formation	226
Cannabinoids	226
Chelation therapy for AD	227
<i>Clioquinol and PBT2</i>	227
<i>Copper chelation by FKBP52</i>	228
<i>Zinc chelation from amyloid plaques</i>	229
<i>Next generation multifunctional chelating agents for AD</i>	229
Heparin and its derivatives	229
<i>A reassessment of the role of heparin in AD</i>	229

<i>Enoxaparin</i>	230
<i>Heparan sulfate</i>	230
Imatinib mesylate.....	230
Laminin.....	231
NSAIDs.....	231
<i>Flurbiprofen analogs with Aβ42-lowering action</i>	232
<i>Nitric oxide-donating NSAIDs</i>	233
<i>In vivo demonstration of the effects of NSAIDs on brain in AD</i>	233
Paclitaxel.....	233
Phenserine.....	234
<i>Tolserine</i>	234
Platinum-based inhibitors of A β	235
Scyllo-cyclohexanehexol.....	235
Ubiquitin C-terminal hydrolase L1.....	235
Drugs to prevent the formation of NFTs.....	235
Tau suppression.....	236
ApoE4 as a therapeutic target in AD.....	237
Strategies to prevent deposits and enhance clearance of Aβ.....	237
4,5-dianilinophthalimide for disruption of A β ₁₋₄₂ fibrils.....	238
ABCA1 overexpression to lower amyloid deposits.....	239
Beta-sheet breakers.....	239
Blocking ApoE/A β interaction to reduce A β plaques.....	239
Clearance of A β across the blood-brain barrier.....	240
Enhanced PKC ϵ activity promotes clearance of A β	240
Galantamine-induced A β clearance.....	240
Inhibitors of A β dehydrogenase.....	241
Intravenous immune globulin.....	241
Meptides.....	242
Monoclonal antibodies for removal of A β	242
Nanotechnology for removal of A β deposits.....	243
Role of matrix metalloproteinases in clearance of A β	243
SAN-61 for cleavage of fibril and soluble amyloid.....	243
Serum amyloid P component depletion.....	244
Small molecule DAPH for clearance of amyloid.....	244
Companies developing Aβ-directed therapeutics for AD.....	244
Antiinflammatory and antimicrobial drugs.....	246
Dapsone.....	246
Antimicrobial drugs against <i>C. pneumoniae</i>	246
PPAR-gamma agonists.....	246
Inhibitors of neuroinflammation.....	247
<i>Cyclophosphamide</i>	247
<i>Etanercept</i>	247
<i>MW01-5-188WH</i>	248
Antidiabetic drugs.....	248
Rosiglitazone.....	248
Pioglitazone.....	249
Nootropics.....	249
Acetyl-L-carnitine.....	249
Cerebrolysin.....	250
Ergot derivatives.....	250
<i>Lisuride</i>	250
<i>Dihydroergocryptine</i>	251
Neuroprotective effect drugs not primarily developed for AD.....	251
Antihypertensive drugs.....	252
<i>Angiotensin-converting enzyme inhibitors</i>	252
<i>Angiotensin receptor blockers</i>	252
Dimebon.....	252
Drugs acting on estrogen receptors.....	253
<i>Estrogen</i>	254
<i>Raloxifene</i>	254
Neurosteroids.....	255
<i>Pregnenolone sulfate</i>	255
<i>Dehydroepiandrosterone</i>	255
Lithium.....	256
MAO-B inhibitors.....	256
<i>Ladostigil tartrate</i>	256
<i>Memoquin</i>	257
Methylene blue.....	257
Nimodipine.....	257
Rapamycin.....	258
Statins.....	258

Testosterone	259
Valproic acid.....	260
Future prospects of neuroprotection in AD.....	260
<i>Targeting Cdk5 pathway</i>	261
Antioxidants	261
Colostrinin	262
Curcumin	262
Melatonin.....	263
Synthetic catalytic scavengers	263
Dehydroascorbic acid.....	263
Omega-3 fatty acids.....	264
Vitamins.....	264
Vitamin E as antioxidant	264
Vitamins to lower homocysteine.....	264
Folic acid	265
Aminopyridazines	265
Nanobody-based drugs for AD	265
Nitric oxide based therapeutics for AD.....	266
Nitric oxide mimetics	266
iNOS inhibitors for AD.....	266
Novel drugs for AD from natural resources	267
Berberine chloride.....	267
Centella asiatica.....	268
Ginko biloba	268
Huperzine-A	269
Hyperforin.....	270
Melissa officinalis	270
Nostocarboline derived from cyanobacteria	270
PTI-00703.....	271
Salvia.....	271
Securinega suffruticosa.....	271
Withania somnifera	271
ZT-1.....	272
Cholesterol and AD	272
ACAT inhibitors	273
Role of gene for cholesterol ester transfer protein	274
Cholesterol 24S-hydroxylase as a drug target for AD.....	274
Selectively increase of ApoA-I production.....	274
Neurotrophic factors	275
Activity-dependent neuroprotective protein	275
Brain derived neurotrophic factor	275
Insulin-like growth factor-1	275
Nerve growth factor	276
Neotrofin (AIT-082).....	277
Limitations of the use of NTFs for AD.....	277
Role of serotonin modulators in AD	278
Xaliproden	278
5-HT _{1A} receptor antagonists	278
5-HT ₆ antagonists	278
5-HT ₄ receptor agonists.....	279
<i>PRX-03140</i>	279
Cell therapy for AD.....	280
Stem cell transplantation for AD	280
<i>Potential benefits of grafting NSCs in AD</i>	280
<i>NSCs improve cognition in AD via BDNF</i>	281
<i>Drugs for enhancing neuronal differentiation of implanted NSCs</i>	281
Implantation of encapsulated cells for delivering NGF	281
Gene therapy for AD	281
ApoE gene therapy.....	282
FGF2 gene transfer in AD.....	282
Humanin gene therapy	282
Nepriylsin gene therapy	282
NGF gene therapy	283
Targeting plasminogen activator inhibitor type-1 gene.....	284
Antisense approaches to AD	284
RNAi approaches to AD	285
Combined therapeutic approaches to AD	286
Drug delivery for Alzheimer disease	286
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	286
Nanoparticle-based drug delivery for Alzheimer's disease.....	287
Transdermal drug delivery in Alzheimer's disease.....	288

<i>Transdermal rivastigmine</i>	288
Intranasal delivery of therapeutics for AD	288
<i>Intranasal delivery of tacrine</i>	288
<i>Intranasal delivery of nerve growth factor to the brain</i>	289
Circadian rhythms and timing of cholinesterase inhibitor therapy	289
Clinical trials for AD	289
Drugs for AD that were discontinued in clinical trials.....	294
Evaluation of clinical trials of AD	296
Monitoring of cognitive function during clinical trials	297
Drug discovery for AD	297
Drugs acting on signaling pathways.....	297
<i>Activation of GTPase signaling by Cytotoxic Necrotizing Factor 1</i>	297
<i>Drugs to reverse inhibition of the PKA/CREB pathway in AD</i>	297
<i>Inhibition of the CD40 signaling pathway</i>	298
<i>JNK pathway as a target</i>	299
<i>Mitogen-activated protein kinase pathway as target</i>	299
<i>Protein kinase C activators</i>	299
Electrophysiological detection of drug target for neuroprotection in early AD	299
Genomics-based drug discovery.....	300
High through screening for AD drug candidates	300
Proteomics and drug discovery for AD	301
Small molecule compounds binding to neurotrophin receptor p75NTR.....	302
<i>Targeting Vav in tyrosine kinase signaling pathway</i>	303
Novels targets/receptors for AD drug discovery	303
<i>Activation of cerebral Rho GTPases</i>	304
<i>Activators of insulin-degrading enzyme</i>	304
<i>Blockade of TGF-β-Smad2/3 signaling in peripheral macrophages</i>	304
<i>Calcium channel blockers</i>	305
<i>Casein kinase 1</i>	305
<i>Cyclin-dependent kinase-5</i>	305
<i>Heat shock protein 90 inhibitors</i>	306
<i>Histone deacetylase 1</i>	306
<i>Inactivation of aph-1 and pen-2 reduces APP cleavage</i>	306
<i>NF-κB inhibitors</i>	307
<i>Kinases and phosphatases as targets for AD therapeutics</i>	307
<i>Neutral sphingomyelinase inhibitors</i>	307
<i>Phosphodiesterase inhibitors</i>	308
<i>Pin 1 as a target in AD</i>	308
<i>Protein phosphatase 5 as a neuroprotective in AD</i>	309
<i>Src homology-containing protein-1 inhibitors</i>	309
<i>Targeting GABAergic system</i>	309
Pharmacogenomics of Alzheimer disease	309
Personalized therapy of AD	310
Genotyping and AD therapeutics	310
Biomarkers and companion diagnostics for AD.....	311
Regulatory aspects of drug development for AD	312
EMA guidelines for drug development for AD	312
Concluding remarks and future prospects of drugs for AD	312
6. Markets & Finances of AD Care	315
Introduction.....	315
Pharmacoeconomics of treatment of AD	315
Quality of Life in relation to economics of AD	315
Costs associated with Alzheimer disease	315
Pharmacoeconomics of donepezil	316
Pharmacoeconomics studies using rivastigmine	316
Pharmacoeconomics studies using galantamine	317
A comparison of pharmacoeconomics outcomes with different ChE inhibitors.....	317
Pharmacoeconomics studies using memantine.....	318
Patterns of AD care in major markets	318
Care of AD patients in the US	318
<i>Cost of care</i>	318
<i>Medicare and AD</i>	319
<i>Patterns of practice in AD care</i>	320
<i>Opinions of physicians' organizations on drugs for dementia</i>	320
Care of AD patients in the UK	321
<i>Cost of care</i>	321
<i>Patterns of practice in AD care</i>	321
<i>Retraction of NICE recommendations to NHS</i>	322
Care of AD patients in Germany	323
Care of AD patients in France	323

Care of AD patients in Italy	324
Care of AD patients in Spain	324
Care of AD patients in Japan	324
Markets for AD diagnostics	325
Markets for AD therapeutics	325
Geographical markets for AD	325
Markets for currently approved drugs for AD	326
Markets for generic AD drugs	326
Future growth of AD market	327
Statins.....	327
Limitations of AD drug development by the biotechnology industry	327
Unmet needs in the management of AD	328
Drivers of AD markets	329
Increase of the aged populations	330
Increase in the number of approved drugs for AD	330
Limitations of the current therapies	330
Improvements in diagnosis	330
Increasing awareness of the disease.....	331
7. Companies	333
Introduction.....	333
Profiles of companies.....	333
Abbott Laboratories	334
AC Immune SA	335
Accera Inc.....	337
Actelion Ltd	338
Acumen Pharmaceuticals Inc	339
Addex Pharmaceuticals	340
Adlyfe Inc	341
Advanced Life Sciences	342
Affiris GmbH.....	343
Allon Therapeutics Inc	344
AlzProtect	345
Amgen Inc	346
Amorfix Life Sciences Ltd	347
Applied NeuroSolutions Inc	348
Archer Pharmaceuticals Inc	349
AstraZeneca	350
Athena Diagnostics Inc	351
Avera Pharmaceuticals Inc	352
Avid Radiopharmaceuticals Inc	353
Avineuro Pharmaceuticals Inc	354
Axon Neuroscience	355
Bayer Healthcare	356
Bayer Pharma AG.....	357
Baxter Healthcare International Inc	358
Bellus Health Inc.....	359
BioArctic Neuroscience AB	360
BiOasis Technologies Inc.....	361
BioE Inc.....	362
Boehringer Ingelheim GmbH	363
Bristol-Myers Squibb Company	364
BTG International Ltd	365
CALBIOCHEM.....	366
Cellzome AG.....	367
CEPHALON Inc.....	368
Ceregene Inc.....	369
Chiesi Farmaceutici SpA.....	370
Circadian Technologies Ltd	371
CoMentis Inc	372
Cortex Pharmaceuticals Inc	373
Cortica Neurosciences.....	374
Crossbeta Biosciences BV	375
Curaxis Pharmaceutical Corporation	376
Cyberonics Inc.....	377
Cytos Biotechnology AG	378
D-Pharm	379
Dainippon Sumitomo Pharma	380
Debiopharm SA.....	381
Diamedica Inc	382
Digilab BioVision GmbH	383

Ebewe Pharma GmbH	384
Eisai Co Ltd	385
Eli Lilly & Co	386
ENKAM Pharmaceuticals A/S.....	387
EnVivo Pharmaceuticals	388
EPIX Pharmaceuticals	389
Evotec AG	390
ExonHit Therapeutics SA.....	391
FluoroPharma Inc.....	392
Forest Laboratories Inc	393
Galantos Pharma GmbH	394
Galapagos Genomics	395
GE Healthcare Ltd	396
GlaxoSmithKline	397
H. Lundbeck A/S	398
Helicon Therapeutics Inc	399
Hoffmann-La Roche Ltd	400
Humanetics Corporation.....	401
Innogenetics NV	402
Intellect Neurosciences Inc.....	403
IntelliHep Ltd.....	404
Interleukin Genetics Inc.....	405
Intra-Cellular Therapies Inc.....	406
ItherX.....	407
JANSSEN Alzheimer Immunotherapy	408
Lay Line Genomics	409
Lexicon Genetics Incorporated	411
Maas BiolAB LLC	412
Medivation Inc.....	413
Merck & Co	414
Merz & Co GmbH	415
MIGENIX Inc	416
MindGenix Inc	417
Mindset BioPharmaceuticals Ltd	418
Mithridion Inc	419
MorphoSys AG.....	420
Myriad Genetics Inc.....	421
Neurimmune Holding AG.....	422
Neuro-Hitech Inc.....	424
Neurologix Inc	425
NeuroMolecular Pharmaceuticals	426
Newron Pharmaceuticals SpA	427
Neuronautics Inc.....	428
NeuroNascent Inc	429
NeuroNova AB	430
Neuroptix Corporation	431
NeuroSearch	432
Noscira	433
Novartis AG.....	434
NsGene.....	435
Nymox Corporation	436
Ortho-McNeil Neurologics Inc.....	437
Osta Biotechnologies Inc.....	438
Panacea Pharmaceuticals Inc.....	439
Pfizer Pharmaceutical Group	440
Pharmexa A/S	441
Pharnext SAS	442
Phytopharm Plc.....	443
Prana Biotechnology Limited.....	444
PrimaBiomed Ltd.....	445
Probiodrug AG	446
Proneuron Biotechnologies Ltd	447
ProteoTech Inc	448
Provista Life Sciences	449
Raptor Pharmaceuticals Corp	450
Reata Pharmaceuticals Inc	452
ReGen Therapeutics Plc	453
reMYND NV	454
Samaritan Pharmaceuticals Inc.....	455
Sanomune Inc	456
Sanochemia Pharmazeutika AG.....	457

Sanofi-Aventis	458
Satoris Inc	459
Savient Pharmaceuticals Inc.....	460
Schwabe Pharmaceuticals	461
Senexis Limited	462
SeneXta Therapeutics SA	464
Servier	465
Sigma-Tau SpA.....	466
Sygnis Pharma AG	467
Takeda Pharmaceutical Corporation.....	468
Targacept Inc	469
TauRx Pharmaceuticals	470
Teva Pharmaceutical Industries Ltd	471
The Genetics Company	472
Thuris Corporation	473
Toyama Chemical Co Ltd.....	474
Transition Therapeutics Inc	475
Translational Genomics Research Institute	476
TransTech Pharma	477
United Biomedical Inc.....	478
Collaborations.....	480

8. References..... 485

Tables

Table 1-1: Historical landmarks relevant to Alzheimer disease	21
Table 1-2: Clinical features of Alzheimer disease.....	22
Table 1-3: Non-Alzheimer dementias.....	27
Table 1-4: A guide to evaluation for MCI due to AD	30
Table 1-5: NINCDS-ADRDA Criteria for diagnosis of Alzheimer disease	31
Table 1-6: Relation of mutations in amyloid precursor protein to CNS disorders.....	40
Table 1-7: Risk factors for Alzheimer's disease	68
Table 1-8: Genes linked to AD	83
Table 1-9: Abnormalities of expression of brain proteins in Down's syndrome and AD	94
Table 2-1: Classification of methods of diagnosis of Alzheimer disease	99
Table 2-2: Neuropsychological test batteries and scales for Alzheimer's disease	100
Table 2-3: Available molecular diagnostic tests for Alzheimer disease.....	106
Table 2-4: Classification of biomarkers of AD in blood and CSF	109
Table 2-5: Characteristics of an ideal biomarker for Alzheimer disease	111
Table 2-6: Role of biomarkers in diagnosis of AD dementia	138
Table 2-7: Companies involved in the diagnosis of Alzheimer disease	139
Table 3-1: Classification of treatments for Alzheimer disease	141
Table 3-2: Cholinergic approaches used in the treatment of Alzheimer disease	142
Table 3-3: Categories of neuroprotective agents for Alzheimer disease	150
Table 3-4: Strategies for prevention of Alzheimer disease	164
Table 3-5: Guidelines for the treatment of dementia	172
Table 4-1: Transgenic mouse models of Alzheimer disease.....	176
Table 5-1: Classification of therapies in development for Alzheimer disease	191
Table 5-2: Drugs for AD targeting nACh receptors	199
Table 5-3: Ionotropic glutamate receptors	201
Table 5-4: Classification of mGluRs	201
Table 5-5: Glutamate receptor modulators as potential therapeutic agents in AD	204
Table 5-6: Companies involved in developing vaccines for AD	219
Table 5-7: Secretase modulators in clinical trials	220
Table 5-8: Companies developing A β -directed therapeutics for AD	244
Table 5-9: Innovative neuroprotective approaches for Alzheimer disease	251
Table 5-10: Herbal therapies for AD	267
Table 5-11: Novel drug delivery methods for Alzheimer disease therapies.....	286
Table 5-12: Clinical trials in Alzheimer disease	289
Table 5-13: Discontinued, failed or inconclusive clinical trials of Alzheimer disease.....	294
Table 6-1: Direct and indirect costs associated with Alzheimer disease	316
Table 6-2: Prevalence of AD in major markets 2011-2021	325
Table 6-3: AD market values from 2011-2021 in major world markets	326
Table 6-4: Markets for currently approved AD drugs 2011-2021	326
Table 6-5: Potential markets for drugs in development 2011-2021.....	327
Table 6-6: Limitations of AD drug discovery and development by the biotechnology industry	328
Table 6-7: Factors that drive AD markets.....	329
Table 7-1: Major players in Alzheimer's disease therapeutics.....	333
Table 7-2: Collaborations relevant to Alzheimer disease	480

Figures

Figure 1-1: Percentages of world population of people over the age of 65 according to more developed and less developed portions – 2000 to 2050.	33
Figure 1-2: Correlation between aging and AD in the US from 2000 to 2020	34
Figure 1-3: Prevalence of different types of dementia.....	35
Figure 1-4: Mechanisms of A β clearance	47
Figure 1-5: Nitric oxide neurotoxicity and neuroprotection in relation to Alzheimer disease	62
Figure 1-6: Oxidative stress and Alzheimer disease	64
Figure 1-7: Role of proteasome inhibition in A β generation and neurodegeneration	68
Figure 1-8: Pathomechanism of AD	80
Figure 3-1: Metabolism of acetylcholine	143
Figure 3-2: Neuroprotective effective of galantamine in AD	147
Figure 3-3: Strategies for the management of Alzheimer disease	174
Figure 5-1: NMDA receptor ion channel complex.	203
Figure 5-2: Neurotoxicity due to misfolding of A β 1-42	238
Figure 5-3: Role of proteomics in drug discovery and development for Alzheimer disease	302
Figure 6-1: Unmet needs in the management of Alzheimer disease	329